Student Research Committee, Department of Medical Biotechnology, School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 19839-63113, Iran.
Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, 1416753955, Iran.
Nanomedicine (Lond). 2019 Aug;14(15):2083-2100. doi: 10.2217/nnm-2018-0379. Epub 2019 Aug 1.
Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review.
卵巢癌是全世界最常见的致死病因之一。不幸的是，化疗未能治愈产生多药耐药性（MDR）的晚期癌症。此外，由于其非特异性毒性，化疗还存在严重的副作用。得益于针对致癌基因和 MDR 相关基因的特异性沉默，纳米 siRNA 药物可能会极大地帮助克服化疗的局限性。在这里，我们综述了基于纳米颗粒的 siRNA 传递策略的最新进展，如聚合体和脂质体系统、刚性纳米颗粒以及与特定配体系统偶联的纳米颗粒。基于纳米颗粒的抗癌药物和针对各种 MDR 机制的 siRNA 的共递药是卵巢癌治疗的前沿策略，本文对此进行了全面讨论。
